{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Squamous+Cell+Carcinoma&page=2", "query": { "condition": "Rectal Squamous Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Squamous+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T19:19:06.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03518554", "title": "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Head and Neck Cancer", "Esophageal Cancer", "Other Metastatic Solid Tumors" ], "interventions": [ { "name": "JAB-3068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2018-04-23", "completion_date": "2022-02-03", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518554" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT00574977", "title": "Safety Study of Modified Vaccinia Virus to Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Cancer", "Head and Neck Squamous Cell Cancer", "Liver Cancer", "Colorectal Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Vaccinia virus (vvDD-CDSR)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "David Bartlett", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2008-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-12-28", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574977" }, { "nct_id": "NCT04472429", "title": "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Anal Canal" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 308, "start_date": "2021-01-12", "completion_date": "2025-09-26", "has_results": true, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 14, "location_summary": "Tucson, Arizona • Duarte, California • Sacramento, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04472429" }, { "nct_id": "NCT00002520", "title": "Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Lymphoma", "Prostate Cancer", "Testicular Germ Cell Tumor", "Tobacco Use Disorder", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "nicotine", "type": "DRUG" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 434, "start_date": "1990-12-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002520" }, { "nct_id": "NCT04000529", "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Esophageal SCC", "Gastrointestinal Stromal Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "TNO155", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2019-07-30", "completion_date": "2024-01-15", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04000529" }, { "nct_id": "NCT05520099", "title": "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunotherapy", "Cancer", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Kidney Cancer", "Clear Cell Renal Cell Cancer (ccRCC)", "Colorectal Cancer", "MSI-H Colorectal Cancer", "DMMR Colorectal Cancer", "Head and Neck Cancer (H&N)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Liver Cancer", "Hepatocellular Carcinoma (HCC)", "Lung Cancer (NSCLC)", "NSCLC (Non-small Cell Lung Cancer)", "Skin Cancer", "Cutaneous Melanoma", "Endometrial Cancer", "Solid Tumor Cancer" ], "interventions": [ { "name": "Core Needle Biopsy, Forceps Biopsy, Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2023-06-26", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Salinas", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520099" }, { "nct_id": "NCT05292859", "title": "Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gynecologic Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Ovary Neoplasm", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Adenosquamous Cell Lung Cancer" ], "interventions": [ { "name": "Neoantigen specific TCR-T cell drug product", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-03-01", "completion_date": "2025-05-30", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292859" }, { "nct_id": "NCT02538627", "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-121", "type": "DRUG" }, { "name": "MM-141", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-08", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 5, "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538627" }, { "nct_id": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Glioblastoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Melanoma", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endocervical Cancer", "Colorectal Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "NGM707", "type": "DRUG" }, { "name": "NGM707 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2021-06-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-06-25T19:19:06.767Z", "location_count": 20, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04913337" } ] }